Advertisement

Esophageal Cancer

  • Jennifer ChuyEmail author
  • Noah Kornblum
Living reference work entry

Abstract

The epidemiology of esophageal cancer has marked variations in different areas of the world. The two major types are squamous cell carcinoma and adenocarcinoma; the latter entity has attracted much attention because of increasing prevalence in the Western nations. The major risk factors for adenocarcinoma include long-standing gastroesophageal reflux disease, Barrett’s metaplasia, and obesity. Risk factors for squamous cell carcinoma include alcoholism and smoking. Manifestations include dysphagia to solids and liquids, weight loss, and aspiration. Diagnosis requires upper endoscopy and target biopsies. Staging requires endoscopic ultrasound and CT imaging of chest and abdomen. Management includes surgery, chemotherapy, and radiation, based on location, stage, and type of cancer, in addition to consideration for age and comorbidities. New options for systemic therapy include targeted therapies and immunotherapy.

Keywords

Obesity Adenocarcinoma Squamous cell carcinoma Esophageal Cigarette smoking and cancer Dysphagia Barrett’s metaplasia GERD 

References

  1. Abnet CC, et al. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J Natl Cancer Inst. 2005;97(4):301–6.PubMedCrossRefGoogle Scholar
  2. Abnet CC, et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer. 2008;44(3):465–71.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Ajani JA, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol. 2007;25(22):3205–9.PubMedCrossRefGoogle Scholar
  4. Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in south Asians: a multicentre case-control study. Eur J Cancer. 2012;48(5):655–61.PubMedCrossRefGoogle Scholar
  5. Al-Batran SE, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.PubMedCrossRefGoogle Scholar
  6. Al-Batran S-E, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35:4004.CrossRefGoogle Scholar
  7. Allum WH, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.PubMedCrossRefGoogle Scholar
  8. al-Sarraf M, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15(1):277–84.PubMedCrossRefGoogle Scholar
  9. Amin MB, Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. Cham: Springer; 2017. xvii, 1024 pages.CrossRefGoogle Scholar
  10. Arnold M, et al. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–55.PubMedCrossRefGoogle Scholar
  11. Balducci L. Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients. J Gastrointest Oncol. 2015;6(1):75–8.PubMedPubMedCentralGoogle Scholar
  12. Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRefGoogle Scholar
  13. Baquet CR, et al. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2005;97(11):1471–8.PubMedPubMedCentralGoogle Scholar
  14. Barreto JC, Posner MC. Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010;16(30):3804–10.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bergman JJ, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc. 2011;74(6):1181–90.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Berry MF, et al. Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. J Thorac Oncol. 2013;8(6):796–802.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Blaydon DC, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet. 2012;90(2):340–6.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Bleiberg H, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–20.PubMedCrossRefGoogle Scholar
  19. Bravi F, et al. Dietary patterns and the risk of esophageal cancer. Ann Oncol. 2012;23(3):765–70.PubMedCrossRefGoogle Scholar
  20. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefGoogle Scholar
  21. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11(2):235–56.PubMedCrossRefGoogle Scholar
  22. Burkart C, et al. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res. 2007;27(4C):2845–8.PubMedGoogle Scholar
  23. Chang AC, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg. 2008;85(2):424–9.CrossRefGoogle Scholar
  24. Chen ZM, et al. Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA. 1997;278(18):1500–4.PubMedCrossRefGoogle Scholar
  25. Chen Z, et al. Incidence and survival differences in esophageal cancer among ethnic groups in the United States. Oncotarget. 2017;8(29):47037–51.PubMedPubMedCentralGoogle Scholar
  26. Choi YJ, et al. The relationship between drinking alcohol and esophageal, gastric or colorectal cancer: a nationwide population-based cohort study of South Korea. PLoS One. 2017;12(10):e0185778.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Chu FS, Li GY. Simultaneous occurrence of fumonisin B1 and other mycotoxins in moldy corn collected from the People’s Republic of China in regions with high incidences of esophageal cancer. Appl Environ Microbiol. 1994;60(3):847–52.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Coleman HG, et al. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26(9):739–45.PubMedCrossRefGoogle Scholar
  29. Cook MB, et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett’s esophagus. Am J Gastroenterol. 2008;103(2):292–300.PubMedCrossRefGoogle Scholar
  30. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101(5):855–9.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Cook MB, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344–53.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Cook MB, et al. Cancer incidence and mortality risks in a large US Barrett’s oesophagus cohort. Gut. 2018;67(3):418–529.PubMedCrossRefGoogle Scholar
  33. Cross AJ, et al. Meat consumption and risk of esophageal and gastric cancer in a large prospective study. Am J Gastroenterol. 2011;106(3):432–42.PubMedCrossRefGoogle Scholar
  34. Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRefGoogle Scholar
  35. Daly JM, Karnell LH, Menck HR. National cancer data base report on esophageal carcinoma. Cancer. 1996;78(8):1820–8.PubMedCrossRefGoogle Scholar
  36. Daly JM, et al. Esophageal cancer: results of an American College of surgeons patient care evaluation study. J Am Coll Surg. 2000;190(5):562–72; discussion 572–3.PubMedCrossRefGoogle Scholar
  37. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017;23(5):751–62.PubMedPubMedCentralCrossRefGoogle Scholar
  38. de Jonge PJ, et al. Barrett’s oesophagus: epidemiology, cancer risk and implications for management. Gut. 2014;63(1):191–202.PubMedCrossRefGoogle Scholar
  39. Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis. 2017;9(Suppl 8):S697–704.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Druesne-Pecollo N, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol. 2009;10(2):173–80.PubMedCrossRefGoogle Scholar
  41. Du X, Hidayat K, Shi BM. Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep. 2017;37(3):BSR20160474Google Scholar
  42. Dubecz A, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012;7(2):443–7.PubMedCrossRefGoogle Scholar
  43. Einzig AI, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol. 1996;13(2):87–93.PubMedCrossRefGoogle Scholar
  44. Ell C, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2000;118(4):670–7.PubMedCrossRefGoogle Scholar
  45. Elsayed H, et al. The influence of age on mortality and survival in patients undergoing oesophagogastrectomies. A seven-year experience in a tertiary Centre. Interact Cardiovasc Thorac Surg. 2010;11(1):65–9.PubMedCrossRefGoogle Scholar
  46. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.PubMedCrossRefGoogle Scholar
  47. Enzinger PC, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736–42.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Ezdinli EZ, et al. Chemotherapy of advanced esophageal carcinoma: eastern cooperative oncology group experience. Cancer. 1980;46(10):2149–53.PubMedCrossRefGoogle Scholar
  49. Fielding RA, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.PubMedCrossRefGoogle Scholar
  50. Findlay M, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5(7):609–16.PubMedCrossRefGoogle Scholar
  51. Freedman ND, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165(12):1424–33.PubMedCrossRefGoogle Scholar
  52. Freedman ND, et al. Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol. 2016;45(3):846–56.PubMedCrossRefGoogle Scholar
  53. Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.PubMedCrossRefGoogle Scholar
  54. Fuchs CS, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Gatenby P, et al. Risk stratification for malignant progression in Barrett’s esophagus: gender, age, duration and year of surveillance. World J Gastroenterol. 2016;22(48):10592–600.PubMedPubMedCentralCrossRefGoogle Scholar
  56. Gerger A, LaBonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J. 2011;17(2):134–41.PubMedCrossRefGoogle Scholar
  57. Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21(4):322–7.PubMedCrossRefGoogle Scholar
  58. Goldblum JR. Barrett’s esophagus and Barrett’s-related dysplasia. Mod Pathol. 2003;16(4):316–24.PubMedCrossRefGoogle Scholar
  59. Gowryshankar A, Nagaraja V, Eslick GD. HER2 status in Barrett’s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol. 2014;5(1):25–35.PubMedPubMedCentralGoogle Scholar
  60. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9.PubMedCrossRefGoogle Scholar
  61. Gross SA, Raimondo M, Conio M. Upper gastrointestinal tumors. Endoscopy. 2007;39(2):110–2.PubMedCrossRefGoogle Scholar
  62. Gustavsson P, et al. Occupational exposures and squamous cell carcinoma of the oral cavity, pharynx, larynx, and oesophagus: a case-control study in Sweden. Occup Environ Med. 1998;55(6):393–400.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.PubMedCrossRefGoogle Scholar
  64. He S, et al. Endoscopic radiofrequency ablation for early esophageal squamous cell neoplasia: report of safety and effectiveness from a large prospective trial. Endoscopy. 2015;47(5):398–408.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Herskovic A, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.PubMedCrossRefGoogle Scholar
  66. Honoré C, et al. Esophageal cancer surgery in patients older than 75: long term results. Acta Chir Belg. 2011;111(1):12–7.PubMedCrossRefGoogle Scholar
  67. Hosch SB, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001;19(7):1970–5.PubMedCrossRefGoogle Scholar
  68. Hoyo C, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the international BEACON consortium. Int J Epidemiol. 2012;41(6):1706–18.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Hurria A, et al. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2014;12(1):82–126.CrossRefGoogle Scholar
  70. Ilhan M, et al. Palmoplantar keratoderma is associated with esophagus squamous cell cancer in Van region of Turkey: a case control study. BMC Cancer. 2005;5:90.PubMedPubMedCentralCrossRefGoogle Scholar
  71. Ilson DH, et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18(5):898–902.PubMedCrossRefGoogle Scholar
  72. Inadomi JM, Saxena N. Screening and surveillance for Barrett’s esophagus: is it cost-effective? Dig Dis Sci. 2018;63(8):2094–104.PubMedCrossRefGoogle Scholar
  73. Iribarren C, et al. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999;340(23):1773–80.PubMedCrossRefGoogle Scholar
  74. Islami F, et al. High-temperature beverages and foods and esophageal cancer risk – a systematic review. Int J Cancer. 2009a;125(3):491–524.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Islami F, et al. Pickled vegetables and the risk of oesophageal cancer: a meta-analysis. Br J Cancer. 2009b;101(9):1641–7.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Islami F, et al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer. 2011;129(10):2473–84.PubMedCrossRefGoogle Scholar
  77. Islami F, et al. A prospective study of tea drinking temperature and risk of esophageal squamous cell carcinoma. Int J Cancer. 2020;146(1):18–25.Google Scholar
  78. Isolauri J, Markkula H. Lye ingestion and carcinoma of the esophagus. Acta Chir Scand. 1989;155(4–5):269–71.PubMedGoogle Scholar
  79. Janjigian YY, Shah MA. Molecularly targeted therapies in advanced gastric cancer. Minerva Gastroenterol Dietol. 2011;57(1):75–88.PubMedGoogle Scholar
  80. Janjigian YY, et al. First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). J Clin Oncol. 2019;37:62.CrossRefGoogle Scholar
  81. Janmaat VT, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017;11:CD004063.PubMedGoogle Scholar
  82. Jatoi A, et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive north central cancer treatment group (NCCTG) trials. Int J Oncol. 2010;36(3):601–6.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefGoogle Scholar
  84. Jiang JM, et al. Smoking and mortality from esophageal cancer in China: a large case-control study of 19,734 male esophageal cancer deaths and 104,846 living spouse controls. Int J Cancer. 2006;119(6):1427–32.PubMedCrossRefGoogle Scholar
  85. Jung KW, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106(8):1447–55; quiz 1456.PubMedPubMedCentralCrossRefGoogle Scholar
  86. Kamangar F, et al. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):27–57, vii.PubMedPubMedCentralCrossRefGoogle Scholar
  87. Kang YK, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.PubMedCrossRefGoogle Scholar
  88. Kato H, et al. Intramural metastasis of thoracic esophageal carcinoma. Int J Cancer. 1992;50(1):49–52.PubMedCrossRefGoogle Scholar
  89. Kelsen DP, et al. Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.PubMedCrossRefGoogle Scholar
  90. Koëter M, et al. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival. Acta Oncol. 2018;57(9):1192–200.PubMedCrossRefGoogle Scholar
  91. Kojima T, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. J Clin Oncol. 2019;37:2.CrossRefGoogle Scholar
  92. Kok TC, van der Gaast A, Splinter TA. 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam esophageal tumor study group. Ann Oncol. 1996;7(5):533–4.PubMedCrossRefGoogle Scholar
  93. Kuipers EJ, Haringsma J. Diagnostic and therapeutic endoscopy. J Surg Oncol. 2005;92(3):203–9.PubMedCrossRefGoogle Scholar
  94. Lange M, et al. Decline in cognitive function in older adults with early-stage breast cancer after adjuvant treatment. Oncologist. 2016;21(11):1337–48.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology. 2006;131(4):1271–83.PubMedCrossRefGoogle Scholar
  96. Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.PubMedPubMedCentralCrossRefGoogle Scholar
  98. Lepage C, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103(11):2694–9.PubMedCrossRefGoogle Scholar
  99. Lester SC, et al. A multi-institutional analysis of Trimodality therapy for Esophageal Cancer in elderly patients. Int J Radiat Oncol Biol Phys. 2017;98(4):820–8.PubMedCrossRefGoogle Scholar
  100. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol. 2005;23(20):4483–9.PubMedCrossRefGoogle Scholar
  101. Liu J, et al. Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer. 2013;133(2):473–85.PubMedCrossRefGoogle Scholar
  102. Lu CL, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21(2):269–74.PubMedCrossRefGoogle Scholar
  103. Madhusudhan C, et al. Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life. Dis Esophagus. 2009;22(4):331–6.PubMedCrossRefGoogle Scholar
  104. Mathieu LN, et al. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2008). Dis Esophagus. 2014;27(8):757–63.PubMedCrossRefGoogle Scholar
  105. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–33.CrossRefGoogle Scholar
  106. Miyata H, et al. Clinical outcome of esophagectomy in elderly patients with and without neoadjuvant therapy for thoracic esophageal cancer. Ann Surg Oncol. 2015;22(Suppl 3):S794–801.PubMedCrossRefGoogle Scholar
  107. Morganstern B, Anandasabapathy S. GERD and Barrett’s esophagus: diagnostic and management strategies in the geriatric population. Geriatrics. 2009;64(7):9–12.PubMedGoogle Scholar
  108. Morita M, et al. Advances in esophageal surgery in elderly patients with thoracic esophageal cancer. Anticancer Res. 2013;33(4):1641–7.PubMedGoogle Scholar
  109. Muro K, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–9.PubMedCrossRefGoogle Scholar
  110. Muro K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–26.PubMedCrossRefGoogle Scholar
  111. Navarro Silvera SA, et al. Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer. 2008;123(4):852–60.PubMedCrossRefGoogle Scholar
  112. Nigro JJ, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg. 1999;117(1):16–23; discussion 23–5.PubMedCrossRefGoogle Scholar
  113. NIH. Cancer stat facts: esophageal cancer. 2019. https://seer.cancer.gov/statfacts/html/esoph.html. Accessed 8 Mar 2019.
  114. Nordenstedt H, El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992–2006). Scand J Gastroenterol. 2011;46(5):597–602.PubMedCrossRefGoogle Scholar
  115. O’Doherty MG, et al. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP diet and health study. Gut. 2012;61(9):1261–8.PubMedCrossRefGoogle Scholar
  116. Okines AF, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20(9):1529–34.PubMedCrossRefGoogle Scholar
  117. Pandeya N, et al. Associations of duration, intensity, and quantity of smoking with adenocarcinoma and squamous cell carcinoma of the esophagus. Am J Epidemiol. 2008;168(1):105–14.PubMedCrossRefGoogle Scholar
  118. Pandeya N, et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology. 2009;136(4):1215–24, e1–2.PubMedCrossRefGoogle Scholar
  119. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.PubMedPubMedCentralCrossRefGoogle Scholar
  120. Parent ME, Siemiatycki J, Fritschi L. Workplace exposures and oesophageal cancer. Occup Environ Med. 2000;57(5):325–34.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Pech O, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014;146(3):652–660.e1.PubMedCrossRefGoogle Scholar
  122. Pickwell SM, Schimelpfening S, Palinkas LA. ‘Betelmania’. Betel quid chewing by Cambodian women in the United States and its potential health effects. West J Med. 1994;160(4):326–30.PubMedPubMedCentralGoogle Scholar
  123. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomark Prev. 2010;19(6):1468–70.CrossRefGoogle Scholar
  124. Pottern LM, et al. Esophageal cancer among black men in Washington, D.C. I. Alcohol, tobacco, and other risk factors. J Natl Cancer Inst. 1981;67(4):777–83.PubMedGoogle Scholar
  125. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(6):822–7.PubMedCrossRefGoogle Scholar
  126. Press MF, et al. HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of Lapatinib. Mol Cancer Ther. 2017;16(1):228–38.PubMedCrossRefGoogle Scholar
  127. Puli SR, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol. 2008;14(10):1479–90.PubMedPubMedCentralCrossRefGoogle Scholar
  128. Randi G, et al. Pipe smoking and cancers of the upper digestive tract. Int J Cancer. 2007;121(9):2049–51.PubMedCrossRefGoogle Scholar
  129. Rasool S, et al. Esophageal cancer: associated factors with special reference to the Kashmir Valley. Tumori. 2012;98(2):191–203.PubMedCrossRefGoogle Scholar
  130. Rastogi A, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394–8.PubMedCrossRefGoogle Scholar
  131. Rex DK, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125(6):1670–7.PubMedCrossRefGoogle Scholar
  132. Rice TW, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016a;29(8):913–9.PubMedPubMedCentralCrossRefGoogle Scholar
  133. Rice TW, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016b;29(8):897–905.PubMedPubMedCentralCrossRefGoogle Scholar
  134. Riedel M, et al. Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study. Chest. 1998;113(3):687–95.PubMedCrossRefGoogle Scholar
  135. Ronkainen J, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–31.PubMedCrossRefGoogle Scholar
  136. Sandler RS, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. 1995;274(17):1359–62.PubMedCrossRefGoogle Scholar
  137. Santibañez M, et al. Occupational exposures and risk of oesophageal cancer by histological type: a case-control study in eastern Spain. Occup Environ Med. 2008;65(11):774–81.PubMedCrossRefGoogle Scholar
  138. Schatz RA, Rockey DC. Gastrointestinal bleeding due to gastrointestinal tract malignancy: natural history, management, and outcomes. Dig Dis Sci. 2017;62(2):491–501.PubMedCrossRefGoogle Scholar
  139. Sgourakis G, Gockel I, Lang H. Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review. World J Gastroenterol. 2013;19(9):1424–37.PubMedPubMedCentralCrossRefGoogle Scholar
  140. Shaheen NJ, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50; quiz 51.PubMedCrossRefGoogle Scholar
  141. Shakhatreh MH, et al. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett’s esophagus. Am J Gastroenterol. 2014;109(12):1862–8; quiz 1861, 1869.PubMedCrossRefGoogle Scholar
  142. Shapiro J, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.PubMedCrossRefGoogle Scholar
  143. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.PubMedPubMedCentralCrossRefGoogle Scholar
  144. Soubeyran P, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829–34.PubMedCrossRefGoogle Scholar
  145. Spechler SJ, Barr H. Review article: screening and surveillance of Barrett’s oesophagus: what is a cost-effective framework? Aliment Pharmacol Ther. 2004;19(Suppl 1):49–53.PubMedCrossRefGoogle Scholar
  146. Stachler MD, et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat Genet. 2015;47(9):1047–55.PubMedPubMedCentralCrossRefGoogle Scholar
  147. Steevens J, et al. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol. 2010a;22(6):669–78.PubMedGoogle Scholar
  148. Steevens J, et al. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 2010b;138(5):1704–13.PubMedCrossRefGoogle Scholar
  149. Steffen A, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;137(3):646–57.PubMedPubMedCentralCrossRefGoogle Scholar
  150. Stevens HP, et al. Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol. 1996;132(6):640–51.PubMedCrossRefGoogle Scholar
  151. Sung H, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88–112.PubMedGoogle Scholar
  152. Tachimori Y, et al. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus. 2011;24(1):33–8.PubMedCrossRefGoogle Scholar
  153. Tepper J, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.PubMedPubMedCentralCrossRefGoogle Scholar
  154. Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.PubMedCrossRefGoogle Scholar
  155. Torre LA, et al. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomark Prev. 2016;25(1):16–27.CrossRefGoogle Scholar
  156. Torres-Aguilera M, Remes Troche JM. Achalasia and esophageal cancer: risks and links. Clin Exp Gastroenterol. 2018;11:309–16.PubMedPubMedCentralCrossRefGoogle Scholar
  157. Tougeron D, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510.PubMedPubMedCentralCrossRefGoogle Scholar
  158. Tramontano AC, et al. Hospice use and end-of-life care among older patients with esophageal cancer. Health Sci Rep. 2018;1(9):e76.PubMedPubMedCentralCrossRefGoogle Scholar
  159. Trivedy C, et al. Copper content in Areca catechu (betel nut) products and oral submucous fibrosis. Lancet. 1997;349(9063):1447.PubMedCrossRefGoogle Scholar
  160. Van der Veen AH, et al. Adenocarcinoma in Barrett’s oesophagus: an overrated risk. Gut. 1989;30(1):14–8.PubMedPubMedCentralCrossRefGoogle Scholar
  161. van Deudekom FJ, et al. Functional and cognitive impairment, social functioning, frailty and adverse health outcomes in older patients with esophageal cancer, a systematic review. J Geriatr Oncol. 2018;9(6):560–8.PubMedCrossRefGoogle Scholar
  162. van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMedCrossRefGoogle Scholar
  163. van Soest EM, et al. Increasing incidence of Barrett’s oesophagus in the general population. Gut. 2005;54(8):1062–6.PubMedPubMedCentralCrossRefGoogle Scholar
  164. van Vliet EP, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547–57.PubMedPubMedCentralCrossRefGoogle Scholar
  165. Vingeliene S, et al. An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk. Ann Oncol. 2017;28(10):2409–19.PubMedPubMedCentralCrossRefGoogle Scholar
  166. Vlacich G, et al. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database. Cancer Med. 2017;6(12):2886–96.PubMedPubMedCentralCrossRefGoogle Scholar
  167. Wang L, et al. Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from northern China. Int J Cancer. 1997;71(5):719–23.PubMedCrossRefGoogle Scholar
  168. Ward EM, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101(1):12–7.PubMedCrossRefGoogle Scholar
  169. Warner E, et al. Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol. 1999;38(2):255–9.PubMedCrossRefGoogle Scholar
  170. Wilke H, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.PubMedCrossRefGoogle Scholar
  171. Włodarczyk JR, Kużdżał J. Stenting in palliation of unresectable esophageal cancer. World J Surg. 2018;42(12):3988–96.PubMedPubMedCentralCrossRefGoogle Scholar
  172. Wobbes T, et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer. 2001;37(4):470–7.PubMedCrossRefGoogle Scholar
  173. Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist. 2014;19(4):367–74.PubMedPubMedCentralCrossRefGoogle Scholar
  174. Wu M, et al. Green tea drinking, high tea temperature and esophageal cancer in high- and low-risk areas of Jiangsu Province, China: a population-based case-control study. Int J Cancer. 2009;124(8):1907–13.PubMedCrossRefGoogle Scholar
  175. Wu M, et al. Smoking and alcohol drinking increased the risk of esophageal cancer among Chinese men but not women in a high-risk population. Cancer Causes Control. 2011;22(4):649–57.PubMedPubMedCentralCrossRefGoogle Scholar
  176. Yau KK, et al. Immediate preoperative laparoscopic staging for squamous cell carcinoma of the esophagus. Surg Endosc. 2006;20(2):307–10.PubMedCrossRefGoogle Scholar
  177. Ychou M, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.PubMedCrossRefGoogle Scholar
  178. Yu C, et al. Hot tea consumption and its interactions with alcohol and tobacco use on the risk for esophageal cancer: a population-based cohort study. Ann Intern Med. 2018;168(7):489–97.PubMedPubMedCentralCrossRefGoogle Scholar
  179. Zagari RM, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–9.PubMedCrossRefGoogle Scholar
  180. Zehetner J, et al. Esophagectomy for cancer in octogenarians. Dis Esophagus. 2010;23(8):666–9.PubMedCrossRefGoogle Scholar
  181. Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 2012;31(6):281–6.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medical OncologyMontefiore Medical CenterBronxUSA

Personalised recommendations